69 related articles for article (PubMed ID: 21508388)
1. Single nucleotide polymorphisms of integrin alpha-2 and beta-3 genes are not associated with relapse-free and overall survival in colorectal cancer patients.
Hofmann G; Langsenlehner U; Langsenlehner T; Glehr M; Gerger A; Absenger G; Szkandera J; Fuerst F; Samonigg H; Krippl P; Renner W
Anticancer Res; 2011 Apr; 31(4):1373-7. PubMed ID: 21508388
[TBL] [Abstract][Full Text] [Related]
2. Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk.
Langsenlehner U; Renner W; Yazdani-Biuki B; Eder T; Wascher TC; Paulweber B; Clar H; Hofmann G; Samonigg H; Krippl P
Breast Cancer Res Treat; 2006 May; 97(1):67-72. PubMed ID: 16317580
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
4. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
[TBL] [Abstract][Full Text] [Related]
5. Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy.
Grau JJ; Caballero M; Monzó M; Muñoz-García C; Domingo-Domenech J; Navarro A; Conill C; Campayo M; Bombí JA
J Surg Oncol; 2008 Aug; 98(2):130-4. PubMed ID: 18537153
[TBL] [Abstract][Full Text] [Related]
6. Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
Fernández-Contreras ME; Sánchez-Hernández JJ; González E; Herráez B; Domínguez I; Lozano M; García De Paredes ML; Muñoz A; Gamallo C
Int J Oncol; 2009 Jan; 34(1):219-29. PubMed ID: 19082493
[TBL] [Abstract][Full Text] [Related]
7. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
8. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
Gal R; Sadikov E; Sulkes J; Klein B; Koren R
Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
10. Integrin alpha-2 and beta-3 gene polymorphisms and colorectal cancer risk.
Gerger A; Hofmann G; Langsenlehner U; Renner W; Weitzer W; Wehrschütz M; Wascher T; Samonigg H; Krippl P
Int J Colorectal Dis; 2009 Feb; 24(2):159-63. PubMed ID: 18836731
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients.
Pardini B; Rosa F; Naccarati A; Vymetalkova V; Ye Y; Wu X; di Gaetano C; Buchler T; Novotny J; Matullo G; Vodicka P
Carcinogenesis; 2015 Jan; 36(1):82-6. PubMed ID: 25368035
[TBL] [Abstract][Full Text] [Related]
12. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
[TBL] [Abstract][Full Text] [Related]
13. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
Gnanasampanthan G; Elsaleh H; McCaul K; Iacopetta B
J Pathol; 2001 Dec; 195(5):543-8. PubMed ID: 11745689
[TBL] [Abstract][Full Text] [Related]
14. An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
Isogai A; Nagaya M; Matsuoka H; Watanabe T; Tsukikawa S; Kubota S
Surgery; 2007 Nov; 142(5):741-8. PubMed ID: 17981195
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
[TBL] [Abstract][Full Text] [Related]
16. SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
Alhopuro P; Alazzouzi H; Sammalkorpi H; Dávalos V; Salovaara R; Hemminki A; Järvinen H; Mecklin JP; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Sep; 11(17):6311-6. PubMed ID: 16144935
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer.
Moreno V; Gemignani F; Landi S; Gioia-Patricola L; Chabrier A; Blanco I; González S; Guino E; Capellà G; Canzian F
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2101-8. PubMed ID: 16609022
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil.
Fernández-Contreras ME; Sánchez-Prudencio S; Sánchez-Hernández JJ; García de Paredes ML; Gisbert JP; Roda-Navarro P; Gamallo C
Int J Oncol; 2006 May; 28(5):1303-10. PubMed ID: 16596248
[TBL] [Abstract][Full Text] [Related]
19. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Balaguer F; Sempere L; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Pons E; Payá A; Alenda C;
Eur J Cancer; 2009 Feb; 45(3):365-73. PubMed ID: 18722765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
